Viamet Pharmaceuticals Holdings

Viamet Pharmaceuticals Holdings was a North Carolina-based biotechnology company focused on discovering and developing small-molecule drugs against validated metalloenzyme targets. The company built its pipeline using a proprietary metal-binding chemistry platform referred to as MIDAS and Metallophile technology, with an initial emphasis on antifungal therapeutics. Its lead historical asset was VT-1161, a fungal CYP51 inhibitor for recurrent vulvovaginal candidiasis and onychomycosis that reached Phase 2b before the operating subsidiary Viamet Pharmaceuticals was acquired by NovaQuest Capital in January 2018. Viamet Pharmaceuticals Holdings retained other platform assets and programs in infectious disease, oncology, and orphan disease after that transaction. The entity later appears to have become inactive/out of business as an independent operating company, with some residual assets and ownership interests referenced in later transactions and Acacia disclosures.